LDL‐cholesterol versus HDL‐cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaos
暂无分享,去创建一个
[1] J. Mehta,et al. Reversal by high-density lipoprotein of the effect of oxidized low-density lipoprotein on nitric oxide synthase protein expression in human platelets. , 1996, The Journal of laboratory and clinical medicine.
[2] J. Borén,et al. Ira Tabas , Kevin Jon Williams and Jan Borén and Therapeutic Implications Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis : Update , 2007 .
[3] Gaochao Zhou,et al. 27-Hydroxycholesterol Is an Endogenous Ligand for Liver X Receptor in Cholesterol-loaded Cells* , 2001, The Journal of Biological Chemistry.
[4] M. Brown,et al. Regulation of low-density lipoprotein receptors: implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis. , 1987, Circulation.
[5] J. Akkerman,et al. Platelet Activation by Low Density Lipoprotein and High Density Lipoprotein , 2006, Pathophysiology of Haemostasis and Thrombosis.
[6] L. Badimón,et al. Low-Density Lipoprotein Upregulates Low-Density Lipoprotein Receptor-Related Protein Expression in Vascular Smooth Muscle Cells: Possible Involvement of Sterol Regulatory Element Binding Protein-2-Dependent Mechanism , 2002, Circulation.
[7] L. Badimón,et al. Importancia del colesterol HDL en la aterotrombosis. ¿De dónde venimos? ¿Hacia dónde vamos? , 2010 .
[8] P. Lesnik,et al. Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.
[9] T. Lüscher,et al. High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease. , 2010, Current pharmaceutical design.
[10] J. Mehta,et al. Inhibition of arterial thrombus formation by ApoA1 Milano. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[11] J. Borén,et al. Molecular Mechanism for Changes in Proteoglycan Binding on Compositional Changes of the Core and the Surface of Low-Density Lipoprotein–Containing Human Apolipoprotein B100 , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[12] D. Stafforini,et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. , 1995, The Journal of clinical investigation.
[13] O. Faergeman,et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.
[14] M. Caulfield,et al. Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.
[15] S. Feasson,et al. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial. , 2008 .
[16] J. Medalie,et al. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[17] G. Norata,et al. Emerging role of high density lipoproteins as a player in the immune system. , 2012, Atherosclerosis.
[18] T. Kita,et al. Identification of soluble forms of lectin-like oxidized LDL receptor-1. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[19] S. Winter,et al. Effects of CP-532,623 and Torcetrapib, Cholesteryl Ester Transfer Protein Inhibitors, on Arterial Blood Pressure , 2009, Journal of cardiovascular pharmacology.
[20] T. Kodama,et al. Macrophage scavenger receptor (SR-A I/II) deficiency reduced diet-induced atherosclerosis in C57BL/6J mice. , 2001, Journal of atherosclerosis and thrombosis.
[21] J. Badimón,et al. Plaque progression and regression in atherothrombosis , 2007, Journal of thrombosis and haemostasis : JTH.
[22] J. Badimón,et al. The role of high-density lipoprotein cholesterol in atherothrombosis. , 2006, The Mount Sinai journal of medicine, New York.
[23] J. Badimón,et al. The role of high-density lipoprotein cholesterol in the prevention and possible treatment of cardiovascular diseases. , 2006, Current molecular medicine.
[24] V. Fuster,et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. , 1994, Journal of the American College of Cardiology.
[25] M. Ezekowitz,et al. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. , 2005, European heart journal.
[26] D. Shih,et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[27] L. Wilkins. Plasma Lipid Distributions in Selected North American Populations: The Lipid Research Clinics Program Prevalence Study THE LIPID RESEARCH CLINICS PROGRAM EPIDEMIOLOGY COMMITTEE , 1979, Circulation.
[28] L. Badimón,et al. Aggregated Low-Density Lipoprotein Uptake Induces Membrane Tissue Factor Procoagulant Activity and Microparticle Release in Human Vascular Smooth Muscle Cells , 2004, Circulation.
[29] S. Kaul,et al. Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. , 1999, The American journal of cardiology.
[30] J. Gamble,et al. Time sequence of the inhibition of endothelial adhesion molecule expression by reconstituted high density lipoproteins. , 2001, Atherosclerosis.
[31] L. Badimón,et al. Atherogenic concentrations of native low-density lipoproteins down-regulate nitric-oxide-synthase mRNA and protein levels in endothelial cells. , 1998, European journal of biochemistry.
[32] M. Hayden,et al. Restoration of Endothelial Function by Increasing High‐Density Lipoprotein in Subjects With Isolated Low High‐Density Lipoprotein , 2003, Circulation.
[33] M. Aviram,et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. , 2000, Circulation.
[34] P. Deedwania,et al. Low high-density lipoprotein cholesterol: current status and future strategies for management , 2010, Vascular health and risk management.
[35] P. McElduff,et al. Low Paraoxonase Activity Predicts Coronary Events in the Caerphilly Prospective Study , 2003, Circulation.
[36] F. Ruschitzka,et al. High-Density Lipoprotein Restores Endothelial Function in Hypercholesterolemic Men , 2002, Circulation.
[37] M. Connelly,et al. Scavenger receptor BI and cholesterol trafficking. , 1999, Current opinion in lipidology.
[38] P. Barter,et al. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells , 2002, Current opinion in lipidology.
[39] G. Vilahur,et al. Lipoproteins, platelets and atherothrombosis. , 2009, Revista espanola de cardiologia.
[40] V. Fuster,et al. Up-regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoA-IMilano , 2008, Journal of cellular and molecular medicine.
[41] K. Saku,et al. Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. , 1985, Thrombosis research.
[42] Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.
[43] H. Sinzinger,et al. Hyperalphalipoproteinemia and prostaglandin I2 stability. , 1997, Thrombosis research.
[44] LinaBadimon,et al. LDL Receptor–Related Protein Mediates Uptake of Aggregated LDL in Human Vascular Smooth Muscle Cells , 2000 .
[45] M. Mims,et al. Altered ultrastructural morphology of self-aggregated low density lipoproteins: coalescence of lipid domains forming droplets and vesicles. , 1991, Journal of lipid research.
[46] L. Badimón,et al. Regulatory effects of HDL on smooth muscle cell prostacyclin release. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[47] A. von Eckardstein,et al. Implications of emerging risk factors for therapeutic intervention. , 2005, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[48] V. Fuster,et al. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. , 1989, Laboratory investigation; a journal of technical methods and pathology.
[49] A. Evans,et al. High expressor paraoxonase PON1 gene promoter polymorphisms are associated with reduced risk of vascular disease in younger coronary patients. , 2002, Atherosclerosis.
[50] A. Tward,et al. Decreased Atherosclerotic Lesion Formation in Human Serum Paraoxonase Transgenic Mice , 2002, Circulation.
[51] S. Ylä-Herttuala. Oxidized LDL and atherogenesis. , 1999, Annals of the New York Academy of Sciences.
[52] D. Gordon,et al. High-Density Lipoprotein Cholesterol and Cardiovascular Disease , 2005 .
[53] D. Haskard,et al. Elevation of Plasma High-Density Lipoprotein Concentration Reduces Interleukin-1–Induced Expression of E-Selectin in an In Vivo Model of Acute Inflammation , 2001, Circulation.
[54] M C Hjortland,et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.
[55] Paul Schoenhagen,et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. , 2007, JAMA.
[56] V. Fuster,et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. , 1999, Circulation.
[57] P. Subbaiah,et al. Effects of Apolipoprotein A-I on ATP-binding Cassette Transporter A1-mediated Efflux of Macrophage Phospholipid and Cholesterol , 2003, Journal of Biological Chemistry.
[58] P. Edwards,et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[59] G. Assmann,et al. High Density Lipoproteins Enhance the Na+/H+ Antiport in Human Platelets , 1996, Thrombosis and Haemostasis.
[60] Thomas Weber,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[61] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.
[62] V. Fuster,et al. Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type). , 2012, Atherosclerosis.
[63] A. von Eckardstein,et al. Suppression of Endothelial Cell Apoptosis by High Density Lipoproteins (HDL) and HDL-associated Lysosphingolipids* , 2001, The Journal of Biological Chemistry.
[64] A. Gotto,et al. HDL Cholesterol and Protective Factors in Atherosclerosis , 2004, Circulation.
[65] S. Yusuf,et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.
[66] Sonia S Anand,et al. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. , 2003, JAMA.
[67] A. Keys,et al. Seven countries. A multivariate analysis of death and coronary heart disease. , 1980 .
[68] D. Shih,et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis , 1998, Nature.
[69] L. Badimón,et al. Experimental and interventional dietary study in humans on the role of HDL fatty acid composition in PGI2 release and Cox‐2 expression by VSMC , 2003, European journal of clinical investigation.
[70] D. Norenberg. Lipid Research Clinics Program , 1984 .
[71] L. Badimón,et al. Sterol regulatory element binding proteins downregulate LDL receptor-related protein (LRP1) expression and LRP1-mediated aggregated LDL uptake by human macrophages. , 2007, Cardiovascular research.
[72] L. Badimón,et al. Adipocyte differentiation-related protein is induced by LRP1-mediated aggregated LDL internalization in human vascular smooth muscle cells and macrophages Published, JLR Papers in Press, July 9, 2007. , 2007, Journal of Lipid Research.
[73] A. von Eckardstein,et al. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. , 1996, Atherosclerosis.
[74] Lina Badimon,et al. LDL receptor-related protein and the vascular wall: implications for atherothrombosis. , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[75] D. Levy,et al. Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.
[76] L. Badimón,et al. LDL receptor-related protein mediates uptake of aggregated LDL in human vascular smooth muscle cells. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[77] H. Lindmark,et al. Inhibitory effects of N‐acetylcysteine on scavenger receptor class A expression in human macrophages , 2002, Journal of internal medicine.
[78] L. Badimón,et al. Intracellular lipid accumulation, low‐density lipoprotein receptor‐related protein expression, and cell survival in vascular smooth muscle cells derived from normal and atherosclerotic human coronaries , 2004, European journal of clinical investigation.
[79] Richard G. W. Anderson,et al. LRP: Role in Vascular Wall Integrity and Protection from Atherosclerosis , 2003, Science.
[80] L. Badimón,et al. Low-density lipoproteins impair migration of human coronary vascular smooth muscle cells and induce changes in the proteomic profile of myosin light chain. , 2008, Cardiovascular research.
[81] C. McNamara,et al. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. , 2008, Arteriosclerosis, thrombosis, and vascular biology.
[82] Peter Libby,et al. Effect of two intensive statin regimens on progression of coronary disease. , 2011, The New England journal of medicine.
[83] G. Vilahur,et al. Update on lipids, inflammation and atherothrombosis , 2011, Thrombosis and Haemostasis.
[84] D. Gordon,et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. , 1989, Circulation.
[85] Raimund Erbel,et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. , 2006, JAMA.
[86] José A Fernández,et al. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. , 1999, The Journal of clinical investigation.
[87] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[88] A. Rigotti,et al. Influence of the HDL Receptor SR-BI on Lipoprotein Metabolism and Atherosclerosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[89] L. Malerød,et al. Oxysterol-activated LXRalpha/RXR induces hSR-BI-promoter activity in hepatoma cells and preadipocytes. , 2002, Biochemical and biophysical research communications.
[90] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[91] C. Sirtori,et al. Plasma lipoproteins affect platelet malondialdehyde and thromboxane B2 production. , 1985, Biochemical medicine.
[92] R. Epand,et al. HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[93] Iftikhar J Kullo,et al. Conditional risk factors for atherosclerosis. , 2005, Mayo Clinic proceedings.
[94] L. Badimón,et al. Sphingosine-1-phosphate: A bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin , 2009, Thrombosis and Haemostasis.
[95] P. Barter. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. , 2009, The American journal of cardiology.
[96] J. Badimón,et al. HDL-induced prostacyclin release in smooth muscle cells is dependent on cyclooxygenase-2 (Cox-2). , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[97] S. Yusuf. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .
[98] L. Badimón,et al. Cell biology and lipoproteins in atherosclerosis. , 2006, Current molecular medicine.
[99] Richard G. W. Anderson,et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase , 2001, Nature Medicine.
[100] L. Badimón,et al. Low-Density Lipoproteins Induce Heat Shock Protein 27 Dephosphorylation, Oligomerization, and Subcellular Relocalization in Human Vascular Smooth Muscle Cells , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[101] L. Badimón,et al. Tissue factor induction by aggregated LDL depends on LDL receptor-related protein expression (LRP1) and Rho A translocation in human vascular smooth muscle cells. , 2007, Cardiovascular research.
[102] Allen J. Taylor,et al. The effect of 24 months of combination statin and extended-release niacin on carotid intima‐media thickness: ARBITER 3* , 2006, Current medical research and opinion.
[103] L. Badimón,et al. Prostacyclin induction by high-density lipoprotein (HDL) in vascular smooth muscle cells depends on sphingosine 1-phosphate receptors: Effect of simvastatin , 2008, Thrombosis and Haemostasis.
[104] Gemma Vilahur,et al. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. , 2008, Journal of the American College of Cardiology.
[105] Roger A. Renfrew,et al. Lipid Research Clinics Program. , 1984, JAMA.
[106] Paul Schoenhagen,et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.